Systemic Sclerosis: From Pathogenesis Towards Targeted Immunotherapies
Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur very early in the disease process, and inflammatory infiltrates in the skin are restricted in early-phase disease. There is good evidence that fibroblast activation with collagen production may be triggered by the immune system. In early-phase disease, we slowly move from general immunosuppression to therapeutically targeting specific molecules involved in immune activation, such as T cell-directed targets, B cell-directed targets, cytokine targets, and tyrosine kinases targets.
No Supplementary Data
Document Type: Research Article
Publication date: 2012-02-01
More about this publication?
- Current Rheumatology Reviews publishes frontier reviews on all the latest advances on rheumatology and its related areas e.g. pharmacology, pathogenesis, epidemiology, clinical care, and therapy. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field.
The journal is essential reading for all researchers and clinicians in rheumatology.